Atherosclerotic peripheral artery disease (PAD) is linked with high rates of cardiovascular conditions and death. More than 10 million people in the United States and 200 million worldwide have atherosclerotic peripheral artery disease (PAD). To restore blood flow to the affected limb, bare metal stents (BMS) (with or without drug elution) are implanted into the affected artery following angioplasty. Problems associated with metal stents include late stent thrombosis and impaired vasomotor function due to the permanent presence of the stent. The bioresorbable vascular scaffolds (BVSs) have received a significant interest in the field since they could provide transient radial strength to resist acute vessel recoil and restore the vessel’s biological properties following stent degradation. However, Current polymer-based BVSs that are under development or FDA approved (Absorb), have larger profile (strut thickness ~ 150 μm) than metal stents (strut thickness 50-80 μm) to maintain the required mechanical strength. These issues increase the risk of thrombosis in small arteries (&lt; 2.5 mm diameter), limiting the vessel sizes that can be treated. In our group, we have been working on a novel stent design and fabrication using polydiolcitrates and additive manufacturing to overcome issues that are believed to be due to the large profile of BVS. Polydiolcitrates are appealing due to their biocompatibility, hemocompatibility, anti-oxidant and drug eluting capability, and tunable mechanical properties. With these motivations, the overall goal of this proposal is to develop a self-expandable, high strength, low profile, drug-eluting BVS via 3D printing
|Effective start/end date
|7/1/18 → 8/10/18
- American Heart Association (18POST34080157)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.